Search

Home > Lung Cancer Considered > FDA Approval: MARIPOSA2, Amivantamab plus Chemotherapy after Osimertinib for EGFR NSCLC
Podcast: Lung Cancer Considered
Episode:

FDA Approval: MARIPOSA2, Amivantamab plus Chemotherapy after Osimertinib for EGFR NSCLC
Category: Science & Medicine
Duration: 00:23:21
Publish Date: 2024-09-17 00:00:00
Description: Description: The FDA approved amivantamab therapy for EGFR mutant NSCLC after progression on osimertinib. This approval is based on the phase III MARIPOSA-2 trial, with data first shared at ESMO 2023 in Madrid with a simultaneous publication in the Annals of Oncology. Lung Cancer Considered host Dr. Stephen Liu talks with two leading oncologists to learn more about how this therapy will be used by clinicians Guest: Dr. Karen Reckamp, Professor of Medicine, Director of the Division of Medical Oncology, and Associate Director of Clinical Research at Cedars-Sinai Medical Center Guest: Dr. William Nassib William, National Leader of Thoracic Oncology at Oncolinicas, Sao Paulo, Brazil
Total Play: 0